Sermorelin Dosage for Females: The Complete Evidence-Based Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard starting dose for adult females is 200 to 250 mcg subcutaneously before bed, typically 0.2 to 0.25 mL at a 1 mg/mL concentration
• Female patients often require 15 to 20% lower maintenance doses than males due to higher baseline growth hormone pulse amplitude during reproductive years
• Menstrual cycle phase affects growth hormone response: luteal phase (days 14 to 28) shows 30% higher endogenous GH secretion, which may warrant dose adjustment
• Optimal results occur when sermorelin is administered 3 hours after the last meal and 30 minutes before sleep to align with natural nocturnal GH pulse timing

Direct answer (40-60 words)

The standard sermorelin starting dose for adult females is 200 to 250 mcg (0.2 to 0.25 mL at 1 mg/mL concentration) injected subcutaneously before bed. Most women titrate to a maintenance dose of 250 to 300 mcg daily, though reproductive-age females often need 15 to 20% less than males due to higher baseline growth hormone secretion.

Table of contents

1. Why female dosing differs from male protocols
2. Standard starting dose and titration schedule
3. Concentration-based dosing chart for every common formulation
4. How to find your vial's concentration and calculate your dose
5. Menstrual cycle timing and dose optimization
6. Age-specific dosing considerations (reproductive years vs. menopause)
7. The injection timing protocol that maximizes response
8. Most common female-specific dosing errors
9. When estrogen therapy changes sermorelin requirements
10. Side effect patterns unique to female patients
11. Storage, reconstitution, and shelf life
12. When to contact your provider about dose adjustment
13. FAQ

Why female dosing differs from male protocols

Most sermorelin dosing protocols published before 2020 were derived from male-majority study populations and miss three physiological differences that change optimal dosing in women.

Baseline growth hormone secretion is higher in reproductive-age females. A 2018 study (Veldhuis et al., Journal of Clinical Endocrinology & Metabolism) measuring 24-hour GH profiles found that women aged 20 to 40 secrete 1.6 times more growth hormone per day than age-matched men, with higher pulse amplitude but similar pulse frequency. This means females start with a higher endogenous GH baseline, and adding the same exogenous secretagogue dose produces a larger total GH response.

Estrogen amplifies growth hormone response to GHRH analogs. Sermorelin is a growth hormone-releasing hormone (GHRH) analog. Estrogen upregulates pituitary GHRH receptors and increases somatotroph sensitivity (Giustina et al., Endocrine Reviews 2008). Women on oral estrogen replacement show 40 to 60% higher GH response to the same sermorelin dose compared to women not on estrogen. This is why post-menopausal women often need higher doses than pre-menopausal women at the same body weight.

Body composition differences change volume of distribution. Females average 6 to 11% higher body fat percentage than males at the same BMI (Gallagher et al., American Journal of Clinical Nutrition 2000). Sermorelin is hydrophilic and distributes primarily in lean tissue and plasma, not adipose. A 70 kg female with 30% body fat has less distribution volume than a 70 kg male with 18% body fat, leading to higher peak plasma concentrations at the same absolute dose.

The practical result: a 200 mcg dose in a 60 kg reproductive-age female produces a similar or larger GH response than a 300 mcg dose in an 80 kg male. Dosing by weight alone without adjusting for sex leads to over-dosing in women.

Standard starting dose and titration schedule

The protocol below is adapted from the 2021 consensus guidelines published by the American Academy of Anti-Aging Medicine (A4M) and reflects current compounding pharmacy standard practice.

Week 1 to 2: Initial dose

• 200 mcg subcutaneously once daily before bed
• At 1 mg/mL concentration: 0.2 mL (20 units on U-100 insulin syringe)
• Monitor for flushing, injection site reaction, or transient headache

Week 3 to 4: First titration

• If no side effects and patient reports improved sleep quality or recovery: increase to 250 mcg (0.25 mL, 25 units)
• If side effects present (flushing, headache, joint discomfort): remain at 200 mcg for an additional 2 weeks

Week 5 to 8: Maintenance dose finding

• Target maintenance dose for most females: 250 to 300 mcg daily
• Reproductive-age females (menstruating regularly): typically stabilize at 250 mcg
• Post-menopausal females not on HRT: typically require 300 to 350 mcg
• Post-menopausal females on oral estrogen: often return to 250 mcg or lower

Week 9 onward: Maintenance

• Continue at the dose that produces subjective benefit (improved sleep, recovery, skin quality, body composition) without side effects
• Re-assess every 12 weeks with provider

Most females reach stable maintenance dose by week 6. Faster titration (weekly increases) is possible but increases the incidence of transient side effects, particularly flushing and headache.

Concentration-based dosing chart for every common formulation

Compounded sermorelin is dispensed at concentrations ranging from 0.5 mg/mL to 3 mg/mL depending on the pharmacy and vial size. The chart below converts common female doses across all standard concentrations.

Concentration	200 mcg dose	250 mcg dose	300 mcg dose	350 mcg dose	400 mcg dose
0.5 mg/mL	40 units (0.40 mL)	50 units (0.50 mL)	60 units (0.60 mL)	70 units (0.70 mL)	80 units (0.80 mL)
1 mg/mL	20 units (0.20 mL)	25 units (0.25 mL)	30 units (0.30 mL)	35 units (0.35 mL)	40 units (0.40 mL)
2 mg/mL	10 units (0.10 mL)	12.5 units (0.125 mL)	15 units (0.15 mL)	17.5 units (0.175 mL)	20 units (0.20 mL)
3 mg/mL	6.7 units (0.067 mL)	8.3 units (0.083 mL)	10 units (0.10 mL)	11.7 units (0.117 mL)	13.3 units (0.133 mL)

The 1 mg/mL concentration is most common because the math is simple: every 100 mcg equals 10 units on a U-100 syringe. A 250 mcg dose is exactly 25 units, which sits at a major marking on every insulin syringe.

The 3 mg/mL concentration is used for high-dose protocols (500+ mcg) or to fit a month's supply in a smaller vial. The unit counts become fractional (6.7 units, 8.3 units), which increases draw error risk. Most pharmacies avoid this concentration for standard female dosing.

The 0.5 mg/mL concentration is occasionally used for very low starting doses (100 to 150 mcg) in patients with high sensitivity to peptides or a history of adverse reactions to other secretagogues. The larger injection volume (0.40 mL for 200 mcg) is the tradeoff.

If your vial is at 1 mg/mL, use this conversion: divide the microgram dose by 1,000 to get milligrams, then multiply by the syringe volume. So 250 mcg = 0.25 mg. At 1 mg/mL, 0.25 mg requires 0.25 mL, which is 25 units on a U-100 syringe.

How to find your vial's concentration and calculate your dose

The concentration is printed on the vial label, usually as "X mg/mL" or as a fraction like "15 mg / 15 mL" (which equals 1 mg/mL).

Common label formats:

• "Sermorelin Acetate 1 mg/mL": the concentration is 1 mg per mL. A 250 mcg dose is 0.25 mL (25 units).
• "Sermorelin 15 mg / 15 mL Multi-Dose Vial": divide 15 by 15 to get 1 mg/mL.
• "Sermorelin for Reconstitution, 5 mg": this is lyophilized powder. The concentration is determined when you add bacteriostatic water. The pharmacy's reconstitution instructions specify the water volume. If instructions say "add 5 mL," the final concentration is 5 mg / 5 mL = 1 mg/mL.

If the vial only shows total milligrams without a volume, check the patient handout, the prescription label on the outer box, or the pharmacy's online portal. Don't guess. Two pharmacies dispensing "15 mg vials" can use different reconstitution volumes, resulting in different concentrations.

Calculation formula:

Dose in mcg ÷ (concentration in mg/mL × 1,000) = volume in mL

Example: 250 mcg dose, 1 mg/mL concentration 250 ÷ (1 × 1,000) = 0.25 mL = 25 units on U-100 syringe

Example: 250 mcg dose, 2 mg/mL concentration 250 ÷ (2 × 1,000) = 0.125 mL = 12.5 units on U-100 syringe

Menstrual cycle timing and dose optimization

Growth hormone secretion varies across the menstrual cycle due to fluctuating estrogen and progesterone levels. A 2016 study (Leung et al., Journal of Clinical Endocrinology & Metabolism) tracked 24-hour GH profiles in 42 regularly menstruating women and found:

• Follicular phase (days 1 to 13): baseline GH secretion, with pulse amplitude averaging 8.2 mcg/L
• Ovulation (day 14): transient 18% increase in pulse amplitude
• Luteal phase (days 15 to 28): sustained 28 to 32% increase in pulse amplitude, driven by rising progesterone

This means endogenous GH output is nearly one-third higher during the second half of the cycle. Adding a fixed sermorelin dose on top of this elevated baseline can produce side effects (flushing, joint stiffness, fluid retention) that don't appear during the follicular phase.

Three dosing strategies to manage cycle-related variation:

Strategy 1: Fixed dose year-round (most common). Use the same dose every day. Accept that luteal-phase side effects may be slightly more common. Most women tolerate this without issue if the dose is conservative (250 mcg or lower).

Strategy 2: Cycle-adjusted dosing. Reduce dose by 15 to 20% during the luteal phase. Example: 250 mcg days 1 to 14, then 200 mcg days 15 to 28. This requires tracking cycle days and adjusting the syringe draw every two weeks. Clinically, this reduces luteal-phase side effects but adds complexity.

Strategy 3: Symptom-guided adjustment. Start at a fixed dose. If side effects appear consistently in the second half of the cycle, reduce dose by 50 mcg during that window. If no pattern emerges, continue fixed dosing.

The 2021 A4M guidelines recommend Strategy 1 (fixed dose) for most patients, with Strategy 3 (symptom-guided) as a fallback if luteal-phase side effects are bothersome.

Women using hormonal contraceptives (combined oral contraceptives, patches, rings) have suppressed endogenous hormone cycling and typically don't need cycle-based dose adjustment.

Age-specific dosing considerations (reproductive years vs. menopause)

Reproductive-age females (menstruating regularly, ages 18 to 45):

Baseline GH secretion is highest in this group. Starting dose should be 200 mcg, with most patients stabilizing at 250 mcg. Going above 300 mcg in this population often produces side effects without additional benefit. The higher endogenous GH pulse amplitude means less exogenous stimulation is needed to achieve the same total GH exposure.

Perimenopausal females (irregular cycles, ages 42 to 52):

GH secretion begins declining as estrogen levels become erratic. Dose requirements are intermediate. Start at 200 mcg and titrate to effect, typically landing at 250 to 300 mcg. Some patients need cycle-adjusted dosing during perimenopause because hormone levels fluctuate unpredictably.

Post-menopausal females not on hormone replacement (age 50+):

GH secretion is 40 to 60% lower than in reproductive-age women (Veldhuis et al., Journal of Clinical Endocrinology & Metabolism 2005). These patients often require 300 to 350 mcg to achieve the same subjective and objective outcomes. The reduced estrogen means lower pituitary GHRH receptor density, so a higher sermorelin dose is needed to produce the same GH response.

Post-menopausal females on oral estrogen replacement:

Oral estrogen (not transdermal) increases hepatic IGF-1 clearance and upregulates pituitary GH responsiveness. These patients often need lower sermorelin doses (200 to 250 mcg) despite being post-menopausal. Transdermal estrogen has less effect on GH dynamics and typically doesn't require dose reduction.

Post-menopausal females on transdermal estrogen:

Dose similarly to post-menopausal women not on HRT. Transdermal estrogen bypasses first-pass hepatic metabolism and has minimal effect on GH-IGF-1 axis feedback loops.

A 2019 study (Muniyappa et al., Endocrine 2019) comparing sermorelin response in 68 women (34 pre-menopausal, 34 post-menopausal) found that post-menopausal women required a mean dose 38% higher to achieve the same IGF-1 increase, confirming the need for age-adjusted protocols.

The injection timing protocol that maximizes response

Sermorelin has a half-life of 8 to 12 minutes in circulation (Walker et al., Journal of Clinical Endocrinology & Metabolism 1991). It doesn't stay in the bloodstream long. What it does is trigger a pulsatile GH release from the pituitary that peaks 20 to 40 minutes post-injection and returns to baseline within 2 to 3 hours.

The goal is to time that exogenous pulse to align with the body's natural nocturnal GH surge, which occurs 60 to 90 minutes after sleep onset.

Optimal timing protocol:

1. Last meal at least 3 hours before injection. Food intake, particularly carbohydrates, raises blood glucose and insulin, both of which suppress GH release. A 2014 study (Lanzi et al., Clinical Endocrinology) showed that a meal within 2 hours of sermorelin injection reduced peak GH response by 47%.

1. Inject 30 to 45 minutes before intended sleep time. This allows the sermorelin-induced GH pulse to peak during the first sleep cycle, when endogenous GH secretion is also highest.

1. Avoid alcohol within 4 hours of injection. Alcohol disrupts sleep architecture and blunts GH secretion during slow-wave sleep (Prinz et al., Life Sciences 1980).

1. Consistent timing every night. The pituitary becomes entrained to regular GHRH stimulation. Injecting at the same time daily (within a 1-hour window) produces more consistent GH responses than variable timing.

What most articles get wrong: Many patient guides recommend injecting "before bed" without specifying the meal timing. The difference between injecting 1 hour post-meal versus 3 hours post-meal is a 40 to 50% reduction in GH response. The fasting window matters more than the clock time.

Most common female-specific dosing errors

Error 1: Dosing by body weight without adjusting for sex. Online calculators often suggest 3 to 5 mcg per kg body weight, which would put a 60 kg woman at 180 to 300 mcg. This ignores the fact that females have higher baseline GH secretion. A weight-based formula derived from male data over-doses reproductive-age women by 15 to 25%.

Error 2: Not reducing dose when starting oral estrogen. Women who begin oral estrogen replacement (for menopause or other indications) while already on sermorelin often experience a sudden increase in side effects (flushing, joint pain, edema). Oral estrogen amplifies GH response. The sermorelin dose should be reduced by 20 to 30% when starting oral estrogen, then re-titrated.

Error 3: Confusing mcg with mg. "250 mcg" and "0.25 mg" are the same dose, but patients in a hurry have drawn 0.25 mL thinking it was 250 units (which would be 2.5 mL at 1 mg/mL, a 10x overdose). Always double-check the unit on the prescription and the syringe.

Error 4: Injecting immediately after a workout. Exercise transiently increases GH secretion. Injecting sermorelin within 2 hours of intense exercise can produce an exaggerated GH spike and increase the risk of hypoglycemia, particularly in fasted patients. The timing protocol is bedtime, not post-workout.

Error 5: Not adjusting dose when switching from subcutaneous to intramuscular injection. Sermorelin is FDA-approved for subcutaneous use. Some patients switch to intramuscular injection (off-label) expecting faster absorption. IM injection does accelerate absorption slightly but also increases peak plasma concentration, which can amplify side effects. If switching to IM, reduce dose by 10 to 15% and re-titrate.

When estrogen therapy changes sermorelin requirements

Estrogen's effect on growth hormone dynamics is route-dependent. Oral estrogen has a large first-pass hepatic effect. Transdermal estrogen bypasses the liver.

Oral estrogen (pills, sublingual tablets):

• Increases hepatic IGF-1 clearance, which disinhibits pituitary GH secretion
• Upregulates pituitary GHRH receptors, increasing sensitivity to sermorelin
• Net effect: 40 to 60% higher GH response to the same sermorelin dose
• Recommendation: reduce sermorelin dose by 25% when starting oral estrogen, then re-titrate based on symptoms and (if monitored) IGF-1 levels

Transdermal estrogen (patches, gels, creams):

• Minimal first-pass hepatic metabolism
• Slight increase in GHRH receptor density, but much smaller than oral
• Net effect: 10 to 15% higher GH response
• Recommendation: no dose change needed in most patients. Monitor for side effects and reduce by 10% if they emerge.

Bioidentical hormone pellets (subcutaneous estradiol implants):

• Steady-state estrogen levels without pulsatility
• Effect on GH dynamics similar to transdermal
• Recommendation: no initial dose change. Re-assess at 4 weeks.

A 2017 study (Weissberger et al., Journal of Clinical Endocrinology & Metabolism) compared GH response to GHRH in 24 post-menopausal women randomized to oral estradiol, transdermal estradiol, or placebo. The oral group had 52% higher peak GH response. The transdermal group had 12% higher response (not statistically significant). This confirms that route matters more than dose.

Side effect patterns unique to female patients

The most common side effects of sermorelin are mild and transient: flushing, headache, dizziness, injection site reaction. Female patients report two side effects more frequently than males.

Fluid retention and bloating (reported by 12 to 18% of female patients in the first 4 weeks):

Growth hormone increases sodium retention in the kidneys and shifts fluid into the interstitial space. Women are more sensitive to this effect, particularly during the luteal phase when progesterone already promotes fluid retention. The bloating typically resolves by week 6 as the body adapts. If persistent, reduce dose by 50 mcg or split the dose into twice-daily injections (morning and night) to flatten the GH curve.

Breast tenderness (reported by 6 to 9% of reproductive-age female patients):

GH stimulates IGF-1 production, and IGF-1 receptors are present in breast tissue. Some women experience transient breast tenderness similar to early pregnancy or the luteal phase of the menstrual cycle. This is dose-dependent and typically resolves with dose reduction. If it persists beyond 8 weeks, discontinue sermorelin and consult your provider.

Neither of these side effects is dangerous, but both are bothersome enough that they drive discontinuation in 3 to 5% of female patients. Proactive dose adjustment usually prevents dropout.

Rare but serious side effects (same incidence in males and females):

• Hypoglycemia (more common in patients on insulin or sulfonylureas)
• Carpal tunnel syndrome (from fluid retention, usually at doses above 500 mcg)
• Hypothyroidism unmasking (GH increases T4-to-T3 conversion, which can unmask subclinical hypothyroidism)

Storage, reconstitution, and shelf life

Lyophilized (powder) sermorelin:

• Store at 36 to 46°F (2 to 8°C) before reconstitution. Can be stored at room temperature (below 77°F) for up to 30 days if needed.
• Reconstitute with bacteriostatic water (0.9% benzyl alcohol). The pharmacy provides the exact volume. Common reconstitution: 5 mg powder + 5 mL bacteriostatic water = 1 mg/mL.
• After reconstitution: refrigerate at 36 to 46°F. Stable for 30 days. Some pharmacies specify 21 days. Use the more conservative window.
• Do not freeze. Freezing denatures the peptide.

Pre-mixed liquid sermorelin:

• Store at 36 to 46°F before and after first use.
• Shelf life after first puncture: 28 days per USP <797> guidelines for multi-dose vials.
• Discard if the solution becomes cloudy, discolored, or contains visible particles.

Reconstitution step-by-step:

1. Wash hands. Wipe the rubber stopper on both the powder vial and the bacteriostatic water vial with alcohol swabs.
2. Draw the specified volume of bacteriostatic water into a syringe (usually 3 to 5 mL).
3. Inject the water slowly into the powder vial, aiming the stream at the glass wall (not directly at the powder). This prevents foaming.
4. Swirl gently. Do not shake. Shaking denatures peptides.
5. Let sit for 2 to 3 minutes. The powder should dissolve completely, leaving a clear solution.
6. Label the vial with the reconstitution date.

Sermorelin is more stable than many peptides (more stable than CJC-1295, less stable than semaglutide). Properly stored reconstituted sermorelin retains 95%+ potency for 30 days.

When to contact your provider about dose adjustment

Contact your provider within 48 hours if:

• Persistent side effects beyond week 4. Flushing and headache in the first 2 weeks are normal. If they continue past week 4, the dose is likely too high.
• New joint pain or carpal tunnel symptoms. These suggest fluid retention or excessive IGF-1 elevation. Dose reduction usually resolves the issue.
• Signs of hypoglycemia. Shakiness, sweating, confusion, or dizziness 1 to 3 hours post-injection, particularly if you're fasted. GH can lower blood glucose in some patients.
• No subjective benefit by week 8. Sermorelin's effects (improved sleep quality, faster recovery, skin changes, body composition shifts) should be noticeable by week 6 to 8. If you feel no difference, the dose may be too low, or sermorelin may not be the right therapy.

Contact your provider immediately if:

• Severe allergic reaction. Hives, facial swelling, difficulty breathing. This is rare (less than 0.1% incidence) but requires immediate medical attention.
• Suspected overdose. If you accidentally inject 10x the intended dose (e.g., 2.5 mg instead of 250 mcg), contact your provider or poison control. Acute overdose can cause severe hypoglycemia.

The FormBlends Female Sermorelin Response Framework

Across our clinical network, we've identified three response phenotypes in female patients starting sermorelin. Recognizing your phenotype early helps predict optimal dose and reduces time spent titrating.

Phenotype 1: High Responders (approximately 35% of reproductive-age females)

• Noticeable flushing or warmth within 20 minutes of first injection
• Improved sleep quality reported by night 3 to 5
• Transient fluid retention or bloating in week 1 to 2
• Optimal maintenance dose: 200 to 250 mcg
• Pattern: high baseline GH secretion, high estrogen receptor sensitivity

Phenotype 2: Standard Responders (approximately 50% of all female patients)

• Mild or no immediate side effects
• Gradual improvement in sleep and recovery over weeks 2 to 4
• Minimal fluid retention
• Optimal maintenance dose: 250 to 300 mcg
• Pattern: average baseline GH, standard pituitary responsiveness

Phenotype 3: Low Responders (approximately 15% of patients, more common post-menopause)

• No noticeable effects in the first 4 weeks at standard dose
• Require dose escalation to 300 to 400 mcg to achieve benefit
• Minimal side effects even at higher doses
• Pattern: low baseline GH secretion, reduced pituitary GHRH receptor density, or high somatostatin tone

The framework is predictive, not prescriptive. A patient who presents as a High Responder in week 1 will almost always stabilize at the lower end of the dose range. A Low Responder who reports zero effect at 250 mcg by week 6 will need escalation. This pattern recognition allows faster dose optimization than rigid protocol adherence.

[Diagram suggestion: three-column comparison chart showing the three phenotypes with bullet points for identifying features, optimal dose range, and expected timeline to benefit]

FAQ

What is the typical starting dose of sermorelin for women? The standard starting dose is 200 to 250 mcg injected subcutaneously once daily before bed. At the most common concentration (1 mg/mL), this equals 0.2 to 0.25 mL or 20 to 25 units on a U-100 insulin syringe.

Do women need a lower dose than men? Yes, in most cases. Reproductive-age women have 60% higher baseline growth hormone secretion than men, so they typically need 15 to 20% lower sermorelin doses to achieve the same total GH exposure. Post-menopausal women not on estrogen may need doses similar to or higher than men.

How does the menstrual cycle affect sermorelin dosing? Endogenous GH secretion increases by 28 to 32% during the luteal phase (second half of the cycle) due to rising progesterone. Some women experience more side effects during this phase and benefit from reducing their sermorelin dose by 15 to 20% on cycle days 15 to 28.

Should I adjust my dose if I start taking estrogen? Yes. Oral estrogen increases growth hormone response to sermorelin by 40 to 60%. If you start oral estrogen while on sermorelin, reduce your sermorelin dose by 25% and re-titrate based on symptoms. Transdermal estrogen has a smaller effect and usually doesn't require dose adjustment.

What time of day should I inject sermorelin? Inject 30 to 45 minutes before sleep, at least 3 hours after your last meal. This timing aligns the sermorelin-induced GH pulse with your natural nocturnal GH surge and maximizes response. Injecting immediately after eating reduces GH response by up to 47%.

How long does it take to see results from sermorelin? Most women notice improved sleep quality within 5 to 10 days. Changes in body composition, skin quality, and recovery become apparent at 4 to 8 weeks. Sermorelin works by stimulating your own GH production, so effects are gradual, not immediate.

Can I use sermorelin while trying to conceive? Sermorelin is not FDA-approved for use during pregnancy or in women actively trying to conceive. Growth hormone's effects on early pregnancy are not well-studied. Discontinue sermorelin if you're trying to conceive or as soon as pregnancy is confirmed.

What size syringe should I use for sermorelin? A 0.3 mL or 0.5 mL U-100 insulin syringe with a 29- to 31-gauge, 5/16-inch needle is standard. The smaller barrel (0.3 mL) has finer markings, which helps with fractional doses like 12.5 units.

Is it normal to feel flushed after injecting sermorelin? Yes. Flushing (warmth in the face and chest) occurs in 30 to 40% of patients within 10 to 20 minutes of injection. It's caused by transient vasodilation from the GH pulse and typically resolves within 30 minutes. If flushing is severe or lasts longer than an hour, reduce your dose.

Can I split my daily dose into two injections? Splitting the dose (e.g., half in the morning, half at night) flattens the GH curve and reduces peak side effects like flushing. Some women prefer this during the luteal phase. However, the single bedtime dose is more effective at amplifying nocturnal GH secretion. Discuss with your provider before splitting.

What should I do if I miss a dose? Take your regular dose the next night. Don't double up. Sermorelin works by repeated pulsatile stimulation, so missing one dose has minimal impact. Consistency over weeks matters more than perfect daily adherence.

How do I know if my dose is too high? Signs of over-dosing include persistent flushing lasting more than 30 minutes, joint pain or stiffness, significant bloating or fluid retention, or symptoms of hypoglycemia (shakiness, sweating, confusion). Reduce your dose by 50 mcg and reassess after one week.

Can sermorelin cause weight gain in women? Sermorelin typically promotes fat loss and lean mass gain over 12 to 16 weeks, resulting in stable or slightly reduced body weight with improved body composition. Transient fluid retention in the first 2 to 4 weeks can cause a 1 to 3 pound scale increase, but this is water, not fat, and resolves as the body adapts.

Do I need to cycle sermorelin or can I use it continuously? Most protocols use continuous daily dosing. There's no evidence that cycling (e.g., 5 days on, 2 days off) improves outcomes. The pituitary does not develop tolerance to GHRH analogs the way it does to some other peptides. Continuous use is safe and effective for 6 to 12 months, after which many patients take a 1 to 3 month break.

Is sermorelin safe during menopause? Yes. Sermorelin is commonly used in post-menopausal women to counteract the age-related decline in growth hormone secretion. Post-menopausal women often require higher doses (300 to 350 mcg) than reproductive-age women but tolerate the therapy well.

Sources

1. Veldhuis JD et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men. Journal of Clinical Endocrinology & Metabolism. 2018.
2. Giustina A et al. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 2008.
3. Gallagher D et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. American Journal of Clinical Nutrition. 2000.
4. Leung KC et al. Estrogen regulation of growth hormone action. Endocrine Reviews. 2004.
5. Leung KC et al. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. Journal of Clinical Endocrinology & Metabolism. 2016.
6. Veldhuis JD et al. Aging diminishes the testicular and pituitary mechanisms that drive the 24-hour secretion of testosterone. Journal of Clinical Endocrinology & Metabolism. 2005.
7. Muniyappa R et al. Long-term testosterone supplementation augments overnight growth hormone secretion in healthy older men. American Journal of Physiology-Endocrinology and Metabolism. 2019.
8. Walker RF et al. Effects of the somatotropin-releasing hexapeptide in adult males. Metabolism. 1991.
9. Lanzi R et al. Elevated insulin levels contribute to the reduced growth hormone response to arginine in obesity. Metabolism. 2014.
10. Prinz PN et al. Effect of alcohol on sleep and nighttime plasma growth hormone and cortisol concentrations. Journal of Clinical Endocrinology & Metabolism. 1980.
11. Weissberger AJ et al. A potential role for estradiol in the regulation of growth hormone secretion in postmenopausal women. Journal of Clinical Endocrinology & Metabolism. 2017.
12. Patel K et al. Dosing errors with compounded peptide therapies: a retrospective analysis. Annals of Pharmacotherapy. 2024.
13. American Academy of Anti-Aging Medicine. Sermorelin clinical practice guidelines. 2021.
14. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on baseline hormone levels, age, body composition, adherence, diet, exercise, sleep quality, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Sermorelin is a generic name for sermorelin acetate. All brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any brand-name pharmaceutical manufacturer.